Transcriptional control: An essential component of cancer gene therapy strategies?

Advanced Drug Delivery Reviews

Volumn 44, Issue 2-3, 2000, Pages 167-184

  Harrington, Kevin J ^a   Linardakis, Emmanouela ^a   Vile, Richard G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Customized promoter; Enhancer; Gene therapy; Inducible promoter; Tissue specific promoter; Tumor specific promoter

Indexed keywords

ONCOLOGY; PATIENT TREATMENT; TISSUE;

CUSTOMIZED PROMOTER; GENE THERAPY; INDUCIBLE PROMOTER; TISSUE SPECIFIC PROMOTER; TUMOR SPECIFIC PROMOTER;

GENETIC ENGINEERING;

DOXYCYCLINE; ECDYSONE; MIFEPRISTONE; RAPAMYCIN; TETRACYCLINE;

ALLOSTERISM; CANCER; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HEAT; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; RADIATION; REVIEW; TISSUE SPECIFICITY; TOXICITY; TRANSCRIPTION REGULATION; TRANSGENE;

ALLOSTERIC REGULATION; ALPHA-FETOPROTEINS; CARCINOEMBRYONIC ANTIGEN; DIMERIZATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMAN; MONOPHENOL MONOOXYGENASE; NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; TRANSCRIPTION, GENETIC;

EID: 0034670078     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(00)00093-4     Document Type: Article

References (116)

1. Progress in transcriptionally targeted and regulatable vectors for genetic therapy
2. Viral vectors for gene therapy
3. Development and application of adenoviral vectors for gene therapy of cancer
4. Nonviral gene therapy: Promises and challenges
5. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA
6. Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences
7. Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter
8. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma
9. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component
10. Effective and safe gene therapy for colorectal carcinoma using the cytosine deaminase gene directed by the carcinoembryonic antigen promoter
11. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma
12. Relative activity and specificity of promoters from prostate-expressed genes
13. In vivo expression of prostate-specific adenoviral vectors in a canine model
14. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer
15. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
16. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines
17. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
18. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
19. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
20. Telomerase in cancer: Diagnostic, prognostic, and therapeutic implications
21. Telomeres, telomerase, and cancer
22. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene
23. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells
24. Characterization of the human L-plastin gene promoter in normal and neoplastic cells
25. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells
26. Hexokinase type II: A novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells
27. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53
28. Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo
29. Use of the glucose starvation-inducible glucose-regulated protein 78 promoter in suicide gene therapy of murine fibrosarcoma
30. Eradication of murine mammary adenocarcinoma through HSVtk expression directed by the glucose-starvation inducible grp78 promoter
31. In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma
32. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach
33. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer
34. Transcriptional targeting of herpes simplex virus for cell-specific replication
35. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo
36. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy
37. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3' to the mouse erythropoietin gene
38. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia
39. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
40. Targeting gene expression to hypoxic tumor cells
41. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer
42. Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type-specific and dose-dependent
43. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy
44. New perspectives in clinical oncology from angiogenesis research
45. Antiangiogenesis for cancer therapy
46. Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery
47. Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector
48. Cell type specificity of the human endoglin promoter
49. Controlling mammalian gene expression with small molecules
50. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
51. Novel retroviral vector transferring a suicide gene and a selectable marker gene with enhanced gene expression by using a tetracycline-responsive expression system
52. Inducible long-term gene expression in brain with adeno-associated virus gene transfer
53. A glial-specific, repressible, adenovirus vector for brain tumor gene therapy
54. Tetracycline-reversible silencing of eukaryotic promoters
55. Transcriptional activation by tetracyclines in mammalian cells
56. Adenovirus-mediated regulable target gene expression in vivo
57. Ligand-dependent regulation of plasmid-based transgene expression in vivo
58. Ecdysone-inducible gene expression in mammalian cells and transgenic mice
59. Control of erythropoietin secretion by doxycycline or mifepristone in mice bearing polymer-encapsulated engineered cells
60. Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization
61. Pharmacologic control of a humanized gene therapy system implanted into nude mice
62. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer
63. A humanized system for pharmacologic control of gene expression
64. Biological consequences of gene regulation after ionizing radiation exposure
65. Radiation induction of immediate early genes: Effectors of the radiation-stress response
66. Spatial and temporal control of gene therapy using ionizing radiation
67. Ionizing radiation activates transcription of the EGR1 gene via CArG elements
68. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells
69. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents
70. Tumor necrosis factor alpha (TNF-α) gene therapy targeted by ionizing radiation selectively damages tumor vasculature
71. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir
72. Induction of the suicide HSV-TK gene by activation of the Egr-1 promoter with radioisotopes
73. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: Activation by ionizing radiation or uptake of radioactive iododeoxyuridine
74. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer
75. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation
76. Heat-inducible vectors for use in gene therapy
77. Control of transgene expression using local hyperthermia in combination with a heat-sensitive promoter
78. On the feasibility of MRI-guided focused ultrasound for local induction of gene expression
79. Gene therapy: Designer promoters for tumour targeting
80. Utilization of variant-type of human alpha-fetoprotein promoter in gene therapy targeting for hepatocellular carcinoma
81. Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy
82. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen
83. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene
84. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice
85. Prostate-specific amplification of expanded polyglutamine expression: A novel approach for cancer gene therapy
86. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component
87. In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors
88. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines
89. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
90. Liver-directed gene therapy: Evaluation of liver specific promoter elements
91. Selective astrocytic transgene expression in vitro and in vivo from the GFAP promoter in a HSV RL1 null mutant vector-potential glioblastoma targeting
92. Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene
93. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity
94. Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator
95. Selective expression of foreign genes in glioma cells: Use of the mouse myelin basic protein gene promoter to direct toxic gene expression
96. Usefulness of a mouse myelin basic protein promoter for gene therapy of malignant glioma: Myelin basic protein promoter is strongly active in human malignant glioma cells
97. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models
98. Chemogene therapy: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model
99. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy
100. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter
101. In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector
102. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression
103. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene
104. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene
105. Hepatoma-specific gene therapy through retrovirus-mediated and targeted gene transfer using an adenovirus carrying the ecotropic receptor gene
106. Gene therapy for cancer using tumour-specific prodrug activation
107. Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors
108. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter
109. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer
110. Engineering tissue-specific expression of a recombinant adenovirus: Selective transgene transcription in the pancreas using the amylase promoter
111. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro
112. Adenovirus-mediated gene therapy of gastric carcinoma using cancer-specific gene expression in vivo
113. Tumor-specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors
114. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene
115. Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells
116. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene